Isomorphic Labs, the AI drug discovery company spun out from Alphabet and led by DeepMind co-founder Demis Hassabis, has secured $2.1 billion in Series B funding. Thrive Capital led the round.
The capital injection marks a major shift from research-focused AI to commercialization. Isomorphic plans to deploy the funding toward scaling its IsoDDE platform, the company's proprietary drug discovery engine, and pushing drug candidates into human clinical trials. This represents the company's first serious pivot toward actually getting AI-discovered drugs into patients.
Isomorphic Labs spun out of DeepMind in 2021 to apply machine learning to molecular biology and drug development. The company has made notable progress modeling protein structures and predicting how drugs interact with targets, building on breakthroughs like AlphaFold. But scaling from computational success to clinical reality requires different expertise: regulatory navigation, manufacturing partnerships, and clinical trial infrastructure.
The $2.1 billion Series B valuation signals investor confidence that AI-discovered compounds can move through the FDA pipeline. However, drug development remains brutally slow and capital-intensive. Even with AI accelerating target identification and compound design, molecules still face years of preclinical testing, IND applications, Phase I, II, and III trials, and regulatory review. The company has entered an entirely different competitive landscape against traditional pharma.
Hassabis and team face a critical test case over the next 3-5 years. Early clinical data from AI-designed candidates will determine whether machine learning fundamentally compresses drug development timelines or merely improves efficiency margins. Success could validate a broader shift in pharma toward AI-native drug pipelines. Failure would suggest the gap between computational promise and biological reality remains wider than the hype suggests.
The funding also reflects broader pharmaceutical interest in AI